Dr. Troy H. Guthrie, Jr.

  • MD
  • Medical Oncologist
  • Spoken languages English

Overview

Career Positions

Current position(s)

  • GenesisCare of Jacksonville, Medical Oncology Division - Medical Oncologist, Jacksonville, FL

Past position(s)

  • Baptist Cancer Institute - Director of Research and Education, Jacksonville, FL
  • University of Florida Health Science Center - Professor of Medicine & Cancer Committee, Jacksonville, FL
  • Baptist Cancer Institute - Director of Research and Education, Jacksonville, FL

Education

Universities

  • University of Georgia, Bachelor's of Science, Zoology and Biology, Athens, GA
  • Medical College of Georgia, Doctor of Medicine, Augusta, GA

Residencies

  • University of Texas Health Science Center San Antonio, Internal Medicine and Hematology, San Antonio, TX

Internships

  • University of Texas Health Science Center San Antonio, San Antonio, TX

Fellowships

  • Medical College of Georgia, Hematology and Oncology, Augusta, GA
  • Hematology and Oncology, Augusta, GA

Expertise And Interests

Interests

  • Breast, Lung, Gastrointestinal and Prostate Cancer, Sickle Cell Anemia, Lymphoma, Melanoma, Renal Cell Carcinoma, and a strong interest on clinical research for state-of-the-art therapy

Accomplishments

Publications

  • Isolated leptomeningeal progression from sinonasal carcinomas: Implications for staging workup and treatment.

Clinical studies

Investigational vaccine to prevent recurrence after surgical resection of stage IIB, IIC or III melanoma. Status: Enrollment On HoldAges Eligible for Study: 18 Years to 80 Years (Adult, Senior)Genders Eligible for Study: Both Histologically confirmed Stage IIb, IIc, III melanoma> Surgical resection within 90 days of first dosing> Persons with positive sentinel nodes must have a complete lymphadenectomy> ECOG performance status 0 or 1Exclusion Criteria:> Any prior melanoma treatment other than surgery or regional irradiation> Diagnosis of non-cutaneous melanoma or melanoma with unknown primary origin> Use of biologic response modifiers within 60 days of first dosing> Subjects with history of other malignancy within past 5 years (with exceptions)

View Study